AZN Stock Recent News
AZN LATEST HEADLINES
VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), which the Company acquired on or about February 3, 2025 (please see news release dated February 3, 2025), has now successfully completed analytical work under contract ("AZ Services Agreement") for AstraZeneca Canada ("AstraZeneca"), contributing to ongoing advancements in pharmaceutical evidence generation. Commissioned by AstraZeneca in consideration for prescribed fees under the AZ Services Agreement (which was entered into on or about September 19, 2024), this work reflects Inka Health's expertise in developing rigorous methodologies to strengthen the reliability of real-world data in healthcare decision-making.
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading days in years, and almost no sector of the economy was spared.
International pharma stocks GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) may have dodged a bullet under Donald Trump's sweeping new tariff regime, according to analysts at Shore Capital. A White House fact-sheet suggests pharmaceutical products will be exempt from the harsher “reciprocal tariffs” aimed at key US trading partners.
UK pharmaceutical giants AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) shares both avoided the wider sell-off on Thursday morning on hopes that drug imports will escape the new 'reciprocal tariffs'. Based on a clarifying fact sheet produced by the White House alongside President Trump's announcement, it appears that pharmaceutical products imported into the US will be exempt from higher-rate tariffs "At least for now," says analyst Sean Conroy at Shore Capital.
AstraZeneca PLC (LSE:AZN) has kept its spot as Bank of America's top pick in the pharmaceutical sector, with analysts raising their earnings forecasts and praising the company's “best-in-class” drug pipeline. The bank reiterated its 'buy' rating and lifted its price target to 14,500p, pointing to a 28% upside from current levels.
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.
AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results could buoy AstraZeneca stock.
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.